Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DOUGLAS WOLF

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1588649693
CMS profile
117322
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$141,431.65

174 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DOUGLAS WOLF

NPI 1588649693 · CMS profile ID 117322

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588649693?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DOUGLAS WOLF, NPI 1588649693, CMS profile ID 117322. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588649693?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DOUGLAS WOLF, NPI 1588649693, CMS profile ID 117322. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588649693?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DOUGLAS WOLF, NPI 1588649693, CMS profile ID 117322, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1588649693?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

174 matching records · $141,431.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 174 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–174 of 174.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $121.4803/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672132245 CMS
PFIZER INC. $4,150.0003/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672251695 CMS
Intercept Pharmaceuticals, Inc. $15.0002/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702104139 CMS
PFIZER INC. $69.1602/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672209035 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,750.0002/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682057035 CMS
PFIZER INC. $14.5002/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672234705 CMS
PFIZER INC. $3,500.0002/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672132477 CMS
PFIZER INC. $227.8202/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672219689 CMS
Janssen Biotech, Inc. $16.6502/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658788503 CMS
PFIZER INC. $19.7602/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672137201 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.0002/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709125775 CMS
PFIZER INC. $14.3902/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672245449 CMS
UCB, Inc. $261.0601/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688234227 CMS
UCB, Inc. $106.7401/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688234001 CMS
UCB, Inc. $268.3901/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688243939 CMS
UCB, Inc. $60.0001/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688243941 CMS
Janssen Biotech, Inc. $12.2401/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658788481 CMS
Merck Sharp & Dohme Corporation $114.0701/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695219607 CMS
PFIZER INC. $4,150.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672157035 CMS
PFIZER INC. $1,052.7601/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672127781 CMS
PFIZER INC. $67.4901/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672182373 CMS
PFIZER INC. $14.3901/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672213121 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,250.0001/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682089215 CMS
PFIZER INC. $16.5301/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672245111 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $141,431.65 174
PY2020 $54,489.13 78
PY2021 $51,438.99 160
PY2022 $102,159.82 166
PY2023 $89,935.78 137
PY2024 $130,118.81 199
PY2025 $98,523.69 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $605,091.48 130
PY2024 Principal investigator $981,273.28 687
PY2023 Recipient $5,410.00 4
PY2023 Principal investigator $612,622.20 77
PY2022 Recipient $3,500.00 4
PY2022 Principal investigator $582,537.23 94
PY2021 Principal investigator $551,766.53 130
PY2020 Recipient $4,600.00 2
PY2020 Principal investigator $1,042,572.81 185
PY2019 Recipient $31,002.80 3
PY2019 Principal investigator $1,377,133.10 101

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

130 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 12/29/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205135
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 12/29/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206461
Principal investigator 1 ABBVIE INC. $10,561.32 12/04/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202527394
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175204410
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204582
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204629
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175204996
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205039
Principal investigator 1 Janssen Research & Development, LLC $3,480.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205067
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205655
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206179
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206369
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206512
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206546
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206773
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206918
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206949
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 10/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175207191
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 10/17/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175207345
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/16/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205082
Principal investigator 1 ABBVIE INC. $1,111.40 10/09/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202514419
Principal investigator 1 PFIZER INC. $1,011.00 10/09/2025 Non-covered Recipient Entity
AGA LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228811737
Principal investigator 1 ABBVIE INC. $307.26 09/04/2025 Non-covered Recipient Entity
AGA LLC
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202510010
Principal investigator 1 ABBVIE INC. $97.50 09/04/2025 Non-covered Recipient Entity
AGA LLC
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202510020
Principal investigator 1 ABBVIE INC. $6,316.80 08/26/2025 Non-covered Recipient Entity
AGA LLC
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202505917
Principal investigator 1 ABBVIE INC. $35,670.20 08/25/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202505661
Principal investigator 1 PFIZER INC. $867.00 08/08/2025 Non-covered Recipient Entity
AGA LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228835389
Principal investigator 1 ABBVIE INC. $2,388.00 08/05/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202501230
Principal investigator 1 ABBVIE INC. $36,870.20 07/28/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202500168
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175204431
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175204453
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175204842
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205060
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205300
Principal investigator 1 Janssen Research & Development, LLC $4,125.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205418
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205426
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206027
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206444
Principal investigator 1 Janssen Research & Development, LLC $343.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206660
Principal investigator 1 Janssen Research & Development, LLC $4,285.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206733
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 07/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175207256
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,227.50 07/16/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Associates
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1235998848
Principal investigator 1 ABBVIE INC. $1,812.80 07/02/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202496615
Principal investigator 1 ABBVIE INC. $7,998.20 07/02/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202496623
Principal investigator 1 Janssen Research & Development, LLC $343.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204337
Principal investigator 1 Janssen Research & Development, LLC $3,992.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204425
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204467
Principal investigator 1 Janssen Research & Development, LLC $343.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205331
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206115
Principal investigator 1 Janssen Research & Development, LLC $3,992.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206396
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206840
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 06/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175207066
Principal investigator 1 PFIZER INC. $3,060.00 06/09/2025 Non-covered Recipient Entity
AGA LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228850214
Principal investigator 1 ABBVIE INC. $5,458.08 06/03/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202487495
Principal investigator 1 ABBVIE INC. $7,399.40 06/03/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202487497
Principal investigator 1 ABBVIE INC. $1,780.70 05/06/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202481921
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175204224
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175204987
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205109
Principal investigator 1 Janssen Research & Development, LLC $4,523.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205464
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205824
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205846
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175205889
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206052
Principal investigator 1 Janssen Research & Development, LLC $4,125.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206429
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206707
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206717
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206926
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206933
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175207168
Principal investigator 1 Janssen Research & Development, LLC $4,125.00 04/28/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175207339
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204530
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204739
Principal investigator 1 Janssen Research & Development, LLC $3,992.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204756
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204927
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205141
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205164
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205581
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205686
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205867
Principal investigator 1 Janssen Research & Development, LLC $4,391.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206469
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206523
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206878
Principal investigator 1 Janssen Research & Development, LLC $3,992.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175207018
Principal investigator 1 Janssen Research & Development, LLC $4,391.00 04/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175207096
Principal investigator 1 PFIZER INC. $1,981.00 04/11/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850125
Principal investigator 1 PFIZER INC. $2,492.00 04/11/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850135
Principal investigator 1 PFIZER INC. $1,274.00 04/11/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850207
Principal investigator 1 ABBVIE INC. $203.20 04/03/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202472289
Principal investigator 1 ABBVIE INC. $1,945.90 04/03/2025 Non-covered Recipient Entity
AGA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202472293
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 03/24/2025 Non-covered Recipient Entity
UNITED DIGESTIVE
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1223276969
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $34,791.91 03/19/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Associates, Llc
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1235998844
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,971.19 03/19/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Associates, Llc
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1235998846
Principal investigator 1 PFIZER INC. $1,624.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854050
Principal investigator 1 PFIZER INC. $2,072.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854060
Principal investigator 1 PFIZER INC. $1,274.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854067
Principal investigator 1 PFIZER INC. $4,179.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854078
Principal investigator 1 PFIZER INC. $4,179.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854157
Principal investigator 1 PFIZER INC. $4,179.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854166
Principal investigator 1 PFIZER INC. $2,492.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854218
Principal investigator 1 PFIZER INC. $1,764.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854872
Principal investigator 1 PFIZER INC. $2,492.00 03/17/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854975
Principal investigator 1 ABBVIE INC. $1,647.60 03/06/2025 Non-covered Recipient Entity
AGA LLC
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202457027
Principal investigator 1 Janssen Research & Development, LLC $1,313.24 03/06/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204895
Principal investigator 1 Celgene Corporation $17,103.27 02/06/2025 Non-covered Recipient Entity
Aga, Llc
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306363
Principal investigator 1 ABBVIE INC. $24,127.30 02/05/2025 Non-covered Recipient Entity
AGA LLC
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202444087
Principal investigator 1 PFIZER INC. $867.00 02/03/2025 Non-covered Recipient Entity
AGA LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228854100
Principal investigator 1 PFIZER INC. $867.00 02/03/2025 Non-covered Recipient Entity
AGA LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228854912
Principal investigator 1 PFIZER INC. $1,011.00 02/03/2025 Non-covered Recipient Entity
AGA LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228854926
Principal investigator 1 PFIZER INC. $1,764.00 02/03/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854934
Principal investigator 1 PFIZER INC. $1,764.00 02/03/2025 Non-covered Recipient Entity
AGA LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854967
Principal investigator 1 Janssen Research & Development, LLC $452.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204389
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204703
Principal investigator 1 Janssen Research & Development, LLC $4,391.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204733
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175204852
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205211
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205260
Principal investigator 1 Janssen Research & Development, LLC $343.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205443
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205794
Principal investigator 1 Janssen Research & Development, LLC $4,391.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175205928
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206684
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206693
Principal investigator 1 Janssen Research & Development, LLC $343.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175206818
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175207040
Principal investigator 1 Janssen Research & Development, LLC $7,950.00 01/30/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175207119
Principal investigator 1 Janssen Research & Development, LLC $4,129.00 01/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206126
Principal investigator 1 Janssen Research & Development, LLC $4,523.00 01/27/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Assoc Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175206677
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,452.00 01/23/2025 Non-covered Recipient Entity
Atlanta Gastroenterology Associates
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1235998850
Principal investigator 1 ABBVIE INC. $3,427.51 01/03/2025 Non-covered Recipient Entity
AGA LLC
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) No dispute reported 06/30/2026 1202436539
Principal investigator 1 ABBVIE INC. $168.00 01/02/2025 Non-covered Recipient Entity
AGA LLC
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202433661